Global Core Electronic Medicinal Product Information (ePI)
1.1.0 - trial-use World

Global Core Electronic Medicinal Product Information (ePI), published by HL7 International / Biomedical Research and Regulation. This guide is not an authorized publication; it is the continuous build for version 1.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/emedicinal-product-info/ and changes regularly. See the Directory of published versions

: ClinicalUseDefinition - Warning Renal Dose Adjustment

Page standards status: Informative

Raw json | Download

{
  "resourceType" : "ClinicalUseDefinition",
  "id" : "cud-diflucan-renal",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-warning-uv-epi"
    ]
  },
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ClinicalUseDefinition cud-diflucan-renal</b></p><a name=\"cud-diflucan-renal\"> </a><a name=\"hccud-diflucan-renal\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-ClinicalUseDefinition-warning-uv-epi.html\">ClinicalUseDefinition Warning (ePI)</a></p></div><p><b>identifier</b>: <code>http://example.org/identifier</code>/cud-diflucan-renal</p><p><b>type</b>: Warning</p><p><b>category</b>: <span title=\"Codes:{http://hl7.org/fhir/uv/emedicinal-product-info/CodeSystem/epi-ig warning}\">Warning</span></p><p><b>subject</b>: <a href=\"Bundle-bundle-epi-type3-example-diflucan.html#http-//hl7.org/fhir/uv/emedicinal-product-info/MedicinalProductDefinition/mpd-diflucan\">MedicinalProductDefinition: identifier = http://ema.europa.eu/identifier#DIFLUCAN-150MG; status = Active</a></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">Active</span></p><p><b>population</b>: <a href=\"Group-group-diflucan-renal.html\">Renal impairment (CrCl ≤ 50 mL/min)</a></p><h3>Warnings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://snomed.info/sct 723188008}\">For multiple-dose therapy, after a normal loading dose, give 50% of the recommended daily dose when CrCl ≤ 50 mL/min (no haemodialysis); give 100% of the recommended dose after each haemodialysis session. Single-dose therapy needs no adjustment. This rule applies to every multiple-dose indication.</span></td></tr></table></div>"
  },
  "identifier" : [
    {
      "system" : "http://example.org/identifier",
      "value" : "cud-diflucan-renal"
    }
  ],
  "type" : "warning",
  "category" : [
    {
      "coding" : [
        {
          "system" : "http://hl7.org/fhir/uv/emedicinal-product-info/CodeSystem/epi-ig",
          "code" : "warning",
          "display" : "Warning"
        }
      ]
    }
  ],
  "subject" : [
    {
      🔗 "reference" : "http://hl7.org/fhir/uv/emedicinal-product-info/MedicinalProductDefinition/mpd-diflucan"
    }
  ],
  "status" : {
    "coding" : [
      {
        "system" : "http://hl7.org/fhir/publication-status",
        "code" : "active",
        "display" : "Active"
      }
    ]
  },
  "population" : [
    {
      🔗 "reference" : "Group/group-diflucan-renal",
      "display" : "Renal impairment (CrCl ≤ 50 mL/min)"
    }
  ],
  "warning" : {
    "code" : {
      "coding" : [
        {
          "system" : "http://snomed.info/sct",
          "code" : "723188008",
          "display" : "Renal insufficiency"
        }
      ],
      "text" : "For multiple-dose therapy, after a normal loading dose, give 50% of the recommended daily dose when CrCl ≤ 50 mL/min (no haemodialysis); give 100% of the recommended dose after each haemodialysis session. Single-dose therapy needs no adjustment. This rule applies to every multiple-dose indication."
    }
  }
}